Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice

Nature Medicine

Volumn 21, Issue 9, 2015, Pages 1085-1090

  Dankbar, Berno ^a   Fennen, Michelle ^a   Brunert, Daniela ^a   Hayer, Silvia ^b   Frank, Svetlana ^a   Wehmeyer, Corinna ^a   Beckmann, Denise ^a   Paruzel, Peter ^a   Bertrand, Jessica ^a   Redlich, Kurt ^b   Koers Wunrau, Christina ^a   Stratis, Athanasios ^a   Korb Pap, Adelheid ^a   Pap, Thomas ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; MYOSTATIN; OSTEOCLAST DIFFERENTIATION FACTOR; SMAD2 PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; COLONY STIMULATING FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; BONE EROSION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GRIP STRENGTH; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; JOINT DESTRUCTION; MALE; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SERUM; SYNOVIUM; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BONE DEVELOPMENT; CELL DIFFERENTIATION; CYTOLOGY; METABOLISM; OSTEOCLAST; PHYSIOLOGY;

ANIMALS; ARTHRITIS, RHEUMATOID; CELL DIFFERENTIATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MYOSTATIN; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; OSTEOGENESIS; RANK LIGAND;

EID: 84941023129     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3917     Document Type: Article

References (41)

1. McPherron, A.C., Lawler, A.M. & Lee, S.J. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 387, 83-90 (1997).
2. Huang, Z., Chen, X. & Chen, D. Myostatin: a novel insight into its role in metabolism, signal pathways, and expression regulation. Cell. Signal. 23, 1441-1446 (2011).
3. Lin, J. et al. Myostatin knockout in mice increases myogenesis and decreases adipogenesis. Biochem. Biophys. Res. Commun. 291, 701-706 (2002).
4. Wagner, K.R., Liu, X., Chang, X. & Allen, R.E. Muscle regeneration in the prolonged absence of myostatin. Proc. Natl. Acad. Sci. USA 102, 2519-2524 (2005).
5. McCroskery, S. et al. Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J. Cell Sci. 118, 3531-3541 (2005).
6. Kellum, E. et al. Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. Bone 44, 17-23 (2009).
7. Hamrick, M.W. et al. Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. Bone 40, 1544-1553 (2007).
8. Hamrick, M.W. Increased bone mineral density in the femora of GDF8 knockout mice. Anat. Rec. A Discov. Mol. Cell. Evol. Biol. 272, 388-391 (2003).
9. Hamrick, M.W., Pennington, C. & Byron, C.D. Bone architecture and disc degeneration in the lumbar spine of mice lacking GDF-8 (myostatin). J. Orthop. Res. 21, 1025-1032 (2003).
10. Nicholson, E.K., Stock, S.R., Hamrick, M.W. & Ravosa, M.J. Biomineralization and adaptive plasticity of the temporomandibular joint in myostatin knockout mice. Arch. Oral Biol. 51, 37-49 (2006).
11. Bialek, P. et al. A myostatin and activin decoy receptor enhances bone formation in mice. Bone 60, 162-171 (2014).
12. Keffer, J. et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025-4031 (1991).
13. Goldring, S.R. Inflammatory mediators as essential elements in bone remodeling. Calcif. Tissue Int. 73, 97-100 (2003).
14. Polzer, K. et al. Interleukin-1 is essential for systemic inflammatory bone loss. Ann. Rheum. Dis. 69, 284-290 (2010).
15. Scott, D.L. et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 39, 122-132 (2000).
16. Goldring, S.R. Pathogenesis of bone erosions in rheumatoid arthritis. Curr. Opin. Rheumatol. 14, 406-410 (2002).
17. Tsuboi, H. et al. Tartrate resistant acid phosphatase (TRAP) positive cells in rheumatoid synovium may induce the destruction of articular cartilage. Ann. Rheum. Dis. 62, 196-203 (2003).
18. Redlich, K. et al. Osteoclasts are essential for TNF-a-mediated joint destruction. J. Clin. Invest. 110, 1419-1427 (2002).
19. Schett, G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res. Ther. 9, 203 (2007).
20. Suzuki, Y., Nishikaku, F., Nakatuka, M. & Koga, Y. Osteoclast-like cells in murine collagen induced arthritis. J. Rheumatol. 25, 1154-1160 (1998).
21. Walsh, N.C., Crotti, T.N., Goldring, S.R. & Gravallese, E.M. Rheumatic diseases: the effects of inflammation on bone. Immunol. Rev. 208, 228-251 (2005).
22. Li, P. et al. RANK signalling is not required for TNF-a-mediated increase in CD11hi osteoclast precursors but is essential for mature osteoclast formation in TNF-a-mediated inflammatory arthritis. J. Bone Miner. Res. 19, 207-213 (2004).
23. Lam, J. et al. TNF-a induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481-1488 (2000).
24. Ritchlin, C.T., Haas-Smith, S.A., Li, P., Hicks, D.G. & Schwarz, E.M. Mechanisms of TNF-a-and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Invest. 111, 821-831 (2003).
25. Bertolini, D.R., Nedwin, G.E., Bringman, T.S., Smith, D.D. & Mundy, G.R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319, 516-518 (1986).
26. Bradley, L., Yaworsky, P.J. & Walsh, F.S. Myostatin as a therapeutic target for musculoskeletal disease. Cell. Mol. Life Sci. 65, 2119-2124 (2008).
27. Fuller, K., Bayley, K.E. & Chambers, T.J. Activin A is an essential cofactor for osteoclast induction. Biochem. Biophys. Res. Commun. 268, 2-7 (2000).
28. Sugatani, T., Alvarez, U.M. & Hruska, K.A. Activin A stimulates I-B-a/NF-B and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J. Cell. Biochem. 90, 59-67 (2003).
29. Tani-Ishii, N., Tsunoda, A., Teranaka, T. & Umemoto, T. Autocrine regulation of osteoclast formation and bone resorption by IL-1 alpha and TNF alpha. J. Dent. Res. 78, 1617-1623 (1999).
30. Korb-Pap, A. et al. Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis. Ann. Rheum. Dis. 71, 1004-1011 (2012).
31. Lee, Z.H. & Kim, H.H. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem. Biophys. Res. Commun. 305, 211-214 (2003).
32. Lee, S.E. et al. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 30, 71-77 (2002).
33. Li, X. et al. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 143, 3105-3113 (2002).
34. Omata, Y. et al. Genome-wide comprehensive analysis reveals critical cooperation between Smad and c-Fos in RANKL-induced osteoclastogenesis. J. Bone Miner. Res. 30, 869-877 (2015).
35. Li, Z.B., Kollias, H.D. & Wagner, K.R. Myostatin directly regulates skeletal muscle fibrosis. J. Biol. Chem. 283, 19371-19378 (2008).
36. Machida, H., Ogawa, K., Funaba, M., Mizutani, T. & Tsujimoto, M. mRNA expression of type I and type II receptors for activin, transforming growth factor-beta, and bone morphogenetic protein in the murine erythroleukemic cell line, F5-5.fl. Eur. J. Endocrinol. 143, 705-710 (2000).
37. Kaneto, H. et al. Increased expression of TGF-β1 but not its receptor contributes to human obstructive nephropathy. Kidney Int. 56, 2137-2146 (1999).
38. Inman, G.J. et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62, 65-74 (2002).
39. Holzbaur, E.L. et al. Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol. Dis. 23, 697-707 (2006).
40. Monach, P.A., Mathis, D. & Benoist, C. The K/BxN arthritis model. Curr. Protoc. Immunol. 81, 15.22.1-15.22.12 (2008).
41. Martinez, G.J. et al. Smad2 positively regulates the generation of Th17 cells. J. Biol. Chem. 285, 29039-29043 (2010).